Who
Damien Alan Perriman
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, eXoZymes.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Apr 2026
- Last trade
- 19 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 25 Aug 2026 | EXOZ eXoZymesBiotechnology | SEC FORM 4 Code M | —19,612 | filing |
| 19 Aug 2026filed 25 Aug 2026 | EXOZ eXoZymesoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,612 at $0.00 | filing |
| 19 Aug 2026filed 25 Aug 2026 | EXOZ eXoZymesoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,612 at $0.00 | filing |
| 19 Aug 2026filed 25 Aug 2026 | EXOZ eXoZymesBiotechnology | SEC FORM 4 Code M | —19,612 | filing |
| 1 Apr 2026filed 8 Apr 2026 | EXOZ eXoZymesBiotechnology | SEC FORM 4 Code A | $75K8,887 at $8.44 | filing |
| 1 Apr 2026filed 8 Apr 2026 | EXOZ eXoZymesBiotechnology | SEC FORM 4 Code A | $75K8,887 at $8.44 | filing |
| 1 Apr 2026filed 8 Apr 2026 | EXOZ eXoZymesBiotechnology | SEC FORM 4 Code A | —62,759 at $0.00 | filing |
| 1 Apr 2026filed 8 Apr 2026 | EXOZ eXoZymesoption or derivative · Biotechnology | SEC FORM 4 Code A | —146,437 at $0.00 | filing |
| 1 Apr 2026filed 8 Apr 2026 | EXOZ eXoZymesoption or derivative · Biotechnology | SEC FORM 4 Code A | —146,437 at $0.00 | filing |
| 1 Apr 2026filed 8 Apr 2026 | EXOZ eXoZymesBiotechnology | SEC FORM 4 Code A | —62,759 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.